OCUMENSION-B: (1) VERY SUBSTANTIAL ACQUISITION IN RELATION TOACQUISITION OF TRANSFERRED PRODUCTS,IN-LICENSING OF LICENSED PRODUCTS AND PROPOSED ISSUE OFCONSIDERATION SHARES UNDER SPECIFIC MANDATEAND(2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TOTHE PURCHASE ARRANGE
OCUMENSION-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
OCUMENSION-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2024
OCUMENSION-B: NOTICE OF BOARD MEETING
OCUMENSION-B: VOLUNTARY ANNOUNCEMENTBIOLOGIC LICENSE APPLICATION FOR OT-702 ACCEPTED BY THENATIONAL MEDICAL PRODUCTS ADMINISTRATION
OCUMENSION-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2024
OCUMENSION-B: POLL RESULTS OF THE ANNUAL GENERAL MEETINGHELD ON JUNE 20, 2024
OCUMENSION-B: (Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2024
OCUMENSION-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2024
OCUMENSION-B: FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BEHELD ON THURSDAY, JUNE 20, 2024
OCUMENSION-B: NOTICE OF ANNUAL GENERAL MEETING
OCUMENSION-B: PROPOSED GRANTING OF GENERAL MANDATESTO ISSUE SHARES AND REPURCHASE SHARES;PROPOSED RE-ELECTION OF RETIRING DIRECTORS;PROPOSED RE-APPOINTMENT OF AUDITOR;PROPOSED AMENDMENTS TO THE 2021 SHARE OPTION SCHEME;PROPOSED AMENDMENTS TO THE 2021 SHARE AWARD SC
OCUMENSION-B: Next Day Disclosure Return
OCUMENSION-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2024
OCUMENSION-B: 2023 Environmental, Social and Governance Report
OCUMENSION-B: 2023 Annual Report
OCUMENSION-B: VOLUNTARY ANNOUNCEMENTPRIMARY ENDPOINTS ACHIEVEDIN THE PHASE III CLINICAL TRIAL OF OT-502 IN CHINA
OCUMENSION-B: VOLUNTARY ANNOUNCEMENTCOMPLETION OF THE PHASE III CLINICALTRIAL OF OT-702 IN CHINA
OCUMENSION-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024
OCUMENSION-B: (I) PROPOSED AMENDMENTS TO THE 2021 SHARE OPTION SCHEME; AND (II) PROPOSED AMENDMENTS TO THE 2021 SHARE AWARD SCHEME
No Data